Physicochemical and Spectroscopic Characteristics of Biofield Treated p-Chlorobenzophenone

Journal: American Journal of Physical Chemistry PDF  

Published: 09-Nov-15 Volume: 4 Issue: 6 Pages: 48-57

DOI: 10.11648/j.ajpc.20150406.12 ISSN: 2327-2430 (Print) 2327-2449 (Online)

Authors: Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Khemraj Bairwa, Snehasis Jana

Citation: Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Khemraj Bairwa, Snehasis Jana. Physicochemical and Spectroscopic Characteristics of Biofield Treated p-Chlorobenzophenone. American Journal of Physical Chemistry. Vol. 4, No. 6, 2015, pp. 48-57. doi: 10.11648/j.ajpc.20150406.12

  • 2509 Views
  • 1207 Downloads

Abstract

p-Chlorobenzophenone (p-CBP) is the important chemical intermediate used for the synthesis of several pharmaceutical drugs like fenofibrate, cetirizine, alprazolam, and benzodiazepine. The aim of this study was set to evaluate the impact of biofield energy treatment on physicochemical and spectroscopic properties of p-CBP. The study was accomplished in two groups i.e. control and treated. The treated group was subjected to Mr. Trivedi’s biofield energy treatment. Subsequently, the control and treated samples of p-CBP were analyzed using X-ray diffraction (XRD), particle size analyzer, surface area analyzer, differential scanning calorimetry (DSC), thermogravimetric analysis-derivative thermogravimetric analysis (TGA-DTG), Fourier transform infrared (FT-IR), and ultraviolet-visible (UV-Vis) spectroscopy. The XRD study exhibited the increase in average crystallite size (25.93%) as well as the intensity of XRD peaks of treated p-CBP, as compared to the control. The particle size analysis showed the reduction in particle size of fine particles (?51.49 ?m) by 21.6% (d10), whereas, increase in particle size of large particles (?433.59 ?m) by 12.82% (d90) and 17.71% (d99), respectively after biofield treatment, as compared to the control. The surface area analysis exhibited the surface area as 0.7005 m2/g in control and 0.7020 m2/g in treated sample of p-CBP. The DSC thermogram of treated p-CBP exhibited the slight decrease in melting temperature. However, the latent heat of fusion was significantly altered (24.90%) after biofield energy treatment as compared to the control. TGA analysis showed the weight loss by 57.36% in control and 58.51% in treated sample. In addition, the onset temperature of thermal degradation was also decreased by 6.32% after biofield energy treatment as compared to the control p- CBP. The FT-IR and UV spectroscopic study did not show the alteration in the wavenumber and wavelength, respectively in treated p-CBP as compared to the control. Altogether, the XRD, particle size and thermal analysis suggest that biofield energy treatment has significant impact on physical and thermal properties of treated p-CBP.

Conclusion

In summary, the XRD diffractogram of biofield treated p-CBP exhibited the increase in intensity of the XRD peaks as well as the average crystallite size (25.93%) as compared to the control. The particle size analysis suggests the decrease in particle size of fine particles (d10) and increase in particle size of the large particles (d90 and d99) with respect to the control sample. The surface area analysis showed the slight increase in the surface area of the treated p-CBP with respect to the control. The thermal analysis (DSC, TGA/DTG) showed a slight decrease in melting temperature and Tmax. However, the ?H was significantly changed by 24.9% in treated sample as compared to the control. The spectroscopic analysis (FT-IR and UV-Vis) suggest that biofield energy treatment did not affect the structural properties of treated sample as compared to the control.

Altogether, it is concluded that the biofield energy treatment has the impact on physicochemical and thermal properties of treated p-CBP with respect to the control. Based on this, it is assumed that biofield treated p-CBP could be more useful as chemical intermediate for organic synthesis of various pharmaceutical drugs.